The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q)

Sylvie Belleville; Andréa C LeBlanc; Marie-Jeanne Kergoat; Frédéric Calon; Pierrette Gaudreau; Sébastien S Hébert; Carol Hudon; Nicole Leclerc; Naguib Mechawar; Simon Duchesne; Serge Gauthier; Consortium for the Early Identification of Alzheimer's disease-Quebec (CIMA-Q)

doi:10.1016/j.dadm.2019.07.003

The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q)

Alzheimers Dement (Amst). 2019 Nov 20:11:787-796. doi: 10.1016/j.dadm.2019.07.003. eCollection 2019 Dec.

Authors

Sylvie Belleville^{1

2}, Andréa C LeBlanc^{3

4}, Marie-Jeanne Kergoat^{2

5}, Frédéric Calon^{6

7}, Pierrette Gaudreau^{8

9}, Sébastien S Hébert^{7

10}, Carol Hudon^{11

12}, Nicole Leclerc^{9

13}, Naguib Mechawar^{14

15}, Simon Duchesne^{12

16}, Serge Gauthier^{14

17}; Consortium for the Early Identification of Alzheimer's disease-Quebec (CIMA-Q)

Collaborators

Consortium for the Early Identification of Alzheimer's disease-Quebec (CIMA-Q):
Pierre Bellec, Sylvie Belleville, Christian Bocti, Frédéric Calon, Howard Chertkow, Louis Collins, Stephen Cunnane, Simon Duchesne, Pierrette Gaudreau, Serge Gauthier, Sébastien S Hébert, Carol Hudon Marie-Jeanne-Kergoat, Andréa C LeBlanc, Nicole Leclerc, Naguib Mechawar, Natalie Philips, Jean-Paul Soucy, Thien Thanh Dang Vu, Louis Verret, Juan Manuel Villalpando

Affiliations

¹ Psychology Department, Université de Montréal, Montreal, Canada.
² Research Center, Institut Universitaire de Gériatrie de Montréal, Montreal, Canada.
³ Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.
⁴ Lady Davis Institute, Jewish General Hospital, Montreal, Canada.
⁵ Department of Geriatric, Université de Montréal, Montreal, Canada.
⁶ Faculty of Pharmacy, Université Laval, Québec, Canada.
⁷ Centre de recherche du CHU de Québec, Université Laval, Québec, Canada.
⁸ Department of Medicine, Université de Montréal, Montreal, Canada.
⁹ Centre Hospitalier de l'Université de Montréal Research Center, Montreal, Canada.
¹⁰ Department of Psychiatry and Neurosciences, Université Laval, Québec, Canada.
¹¹ School of Psychology, Université Laval, Québec, Canada.
¹² Centre de recherche CERVO, Institut Universitaire en Santé Mentale de Québec, Quebec, Canada.
¹³ Department of Neurosciences, Université de Montréal, Montreal, Canada.
¹⁴ Department of Psychiatry, McGill University, Montreal, Canada.
¹⁵ Douglas Mental Health University Institute, Montreal, Canada.
¹⁶ Department of Radiology and Nuclear Medicine, Université Laval, Québec, Canada.
¹⁷ McGill Center for Studies in Aging, Montreal, Canada.

Abstract

Introduction: The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia.

Methods: CIMA-Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community.

Results: In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well as blood and peripheral blood mononuclear cells collections. Among them, 142 underwent magnetic resonance imaging, 29 a ¹⁸fluorodeoxyglucose positron emission tomography, and 60 a lumbar puncture.

Discussion: CIMA-Q provides procedures and resources to identify early biomarkers and novel therapeutic targets, and holds promise for detecting cognitive decline in Alzheimer's disease.

Keywords: Alzheimer's disease; Biomarker; CIMA-Q; Clinical cohort; Consortium for the early identification of Alzheimer's disease-Quebec; Cryopreserved PBMNC; Early diagnosis; Mild cognitive impairment; Subjective cognitive decline.